|Bid||161.8500 x 100|
|Ask||162.2000 x 400|
|Day's range||161.1500 - 171.5750|
|52-week range||63.9000 - 222.0300|
|PE ratio (TTM)||N/A|
|Earnings date||20 Feb 2018 - 26 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||199.59|
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has issued an additional 277,109 shares of common stock at the public offering price of $185 per share, for total gross proceeds of approximately $51.3 million, pursuant to the partial exercise ...
bluebird bio, Inc. , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunothe
PARIS--(BUSINESSWIRE)-- Blue Frog Robotics , the creator of “BUDDY” – one of the most advanced home, education and entertainment robots, formalizes today a new round of funding, finalized last November. ...
Juno is now the cheapest CAR-T player, an analyst said Wednesday as he downgraded rival Bluebird on a lack of catalysts until the spring.
A next-generation cancer treatment could significantly change multiple myeloma outcomes for thousands of people, generating hundreds of millions of dollars in sales for the company.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share, before underwriting discounts.
Stocks that moved substantially or traded heavily Monday: Bluebird Bio Inc., up $30.65 to $201.80 Bluebird and Celgene reported positive results from an early clinical trial of a multiple myeloma treatment. ...
Bluebird Bio Inc.'s soaring stock price hit a bit of turbulence Monday afternoon, after the company said it planned to sell $600 million in fresh shares amid a run to record prices. Bluebird shares have ...
bluebird bio, Inc. , a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced that it has commenced an underwritten public offering of $600 million of its common stock.
Biotech stocks were active Monday as analysts weighed in on a raft of announcements from companies attending the American Society of Hematology annual meeting.
More than 50 years after the cause of sickle-cell disease was discovered, a dozen treatments for the painful and life-shortening inherited condition offer hope for long-overlooked patients.
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Stocks were trading higher Monday, as bitcoin futures began trading, and an explosion in New York's Port Authority Bus Terminal that injured only the suspect. S&P futures are up 0.1%. Dow Jones Industrial ...